The biopharma funding engine motors on, as Chinese biotech raises nearly $280M in monster round
We have more evidence today that the appetite for biopharma financing is alive and kicking, the coronavirus pandemic be damned.
Reports emerged on Wednesday that Shanghai-based Mabwell Biotech has raised a mammoth $278.5 million in a Series A injection, led by Chinese venture capital firm Shiyu Capital.
Mabwell, established in 2017, develops monoclonal antibodies and long-acting recombinant proteins, among other drugs, and is expected to debut its first drug on the market this year. The company has also launched seven subsidiaries focused on R&D and the production of biomedical products.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters